Alternative Data for Outlook Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 34,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 154 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,820 | Sign up | Sign up | Sign up |
| X Followers | 1,050 | Sign up | Sign up | Sign up |
| X Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 21 | Sign up | Sign up | Sign up |
| Linkedin Employees | 61 | Sign up | Sign up | Sign up |
About Outlook Therapeutics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
| Price | $0.45 |
| Target Price | Sign up |
| Volume | 1,674,222 |
| Market Cap | $34M |
| Year Range | $0.39 - $2.97 |
| Dividend Yield | 0% |
| PE Ratio | 0.59 |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)March 5 - GlobeNewswire |
|
Outlook Therapeutics Strikes Commercial Distribution Agreement To Sell, Distribute LYTENAVA In SwitzerlandFebruary 18 - Benzinga |
|
HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $0.5 Price TargetFebruary 17 - Benzinga |
|
Outlook Therapeutics shares are trading lower after the company announced worse-than-expected Q1 financial results.February 16 - Benzinga |
|
 |
Outlook Therapeutics Earnings Report: Q1 OverviewFebruary 16 - Benzinga |
Outlook Therapeutics Q1 Adj. EPS $(0.22) Misses $(0.18) Estimate, Sales $(1.208M) Miss $5.025M EstimateFebruary 16 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | -92,000 | 920,000 | -1M | -13M | 0 | -0.290 |
| Q2 '25 | 1.5M | 440,000 | 1.1M | -20M | -20M | -0.550 |
| Q1 '25 | 0 | 29,000 | -29,000 | -46M | -12M | -0.337 |
| Q4 '24 | 170,000 | 29,000 | -29,000 | 17M | -22M | -0.890 |
| Q3 '24 | 170,000 | 85,000 | 85,000 | 5.7M | 5.7M | -0.937 |
Insider Transactions View All
| KENYON LAWRENCE A filed to buy 5,946 shares at $5.7. September 30 '24 |
| Syntone Ventures LLC filed to buy 1,705,438 shares at $0. April 17 '24 |
| Syntone Ventures LLC filed to buy 1,071,429 shares at $0. April 17 '24 |
| Haddadin Yezan Munther filed to buy 5,049 shares at $11.8. March 29 '24 |
| Evanson Jeff filed to buy 808,459 shares at $0.4. March 11 '24 |
Similar companies
Read more about Outlook Therapeutics (OTLK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Outlook Therapeutics
The Market Cap of Outlook Therapeutics is $34M.
As of today, Outlook Therapeutics' PE (Price to Earnings) ratio is 0.59.
Currently, the price of one share of Outlook Therapeutics stock is $0.45.
The OTLK stock price chart above provides a comprehensive visual representation of Outlook Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Outlook Therapeutics shares. Our platform offers an up-to-date OTLK stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Outlook Therapeutics (OTLK) does not offer dividends to its shareholders. Investors interested in Outlook Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Outlook Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
